Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
Year: 2023
Type: supplementary-materials
Abstract: Serum IFNγ, IL-10, and IL-2 AUC0–28 (ng/mL)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4387602132